NovaBay Pharmaceuticals (NBY) Stock: Buy, Sell, or Hold?
$1.95
+0.36 (+22.64%)
â˛
5d:
+27.45%
30d:
+33.56%
90d:
-65.43%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (76%)
Quality Score
43/100
Position
FAIR
Forward P/E & Valuation
42.0x
Next 12M consensus est.
Wall Street Target
$0.85
-56.4% vs target
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$1.13 / $1.98
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: NBY is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When NBY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: NBY is currently trading at $1.95, which is considered fair based on recent price action.
Technical Outlook: Technically, NBY is in a uptrend. The price is approaching resistance at $1.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.6% recently.
Market Sentiment: NBY scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $0.85. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NBY is in a uptrend. The price is approaching resistance at $1.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.6% recently.
Market Sentiment: NBY scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $0.85. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
43/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
76.3%
Trading Range & Key Levels
Support Level
$1.13
Resistance Level
$1.98
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+22.6%)
- BEARISH: Trading 56.4% above Wall St target ($0.85)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
42.02
Wall Street Target
$0.85
(-56.4%)
Revenue Growth (YoY)
-78.7%
Share NBY Analysis
Share this live NBY analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NBY)
Bullish
3 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Mar 30, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits messages indicate a bullish outlook for $NBY, with no news articles available to provide additional context.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 5:34 PM ET
Data refreshes hourly during market hours. Next update: 6:34 PM
Data refreshes hourly during market hours. Next update: 6:34 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBY showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$91 | 54 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 58 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 42 HOLD |
|
RAPP
Rapport Therapeutics, InâĻ |
STRONG BUY
16 analysts |
$64 | 49 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NBY Research Pages
